Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > ARCHIVE
ARCHIVE
- Functional health food system to start april
April 2, 2001
- REGULATORY NEWS IN BRIEF
April 2, 2001
- COX-2 Inhibitors Show Effects against Cancer
April 2, 2001
- Korosho Urges Generic Makers to Ensure Stable Supply of Their Products
April 2, 2001
- Korosho Supplies Anti-AIDS Drugs Unapproved in Japan to 393 Patients
March 26, 2001
- Kissei, Daiichi to Codevelop Agent for Dysuria
March 26, 2001
- BULLETIN
March 26, 2001
- Kissei to Market Sumitomo's Falecalcitriol
March 26, 2001
- Government Council Proposes Lump-sum Payment by Type, Severity of Illness
March 26, 2001
- Pharmacia's Solu-Medrol Approved for Bronchial Asthma
March 26, 2001
- HPB Creates Study Team on Insurance Healthcare Information Systems
March 26, 2001
- JPMA to Create Consortium for Analysis of Protein Structure in FY2001
March 26, 2001
- Evidence-Based Treatment for Ischemic Heart Disease Needed
March 26, 2001
- Freund Creates New Company to Contract Manufacture Investigational New Drugs in US
March 26, 2001
- Company Reform Is Half-way Point to Top of Mountain: Takeda
March 26, 2001
- Fibrate Drugs Effective against Hypertriglyceridemia
March 26, 2001
- Clinical Trials Must Be Promoted from the Patients' Viewpoint: Prof. Nakano
March 26, 2001
- Seiwa Sangyo Introduces New System to Cut Costs
March 26, 2001
- WORLD NEWS IN BRIEF
March 26, 2001
- Introduction of CRC Certification System Being Considered
March 26, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…